These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8903286)

  • 1. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group.
    Cullen SI
    South Med J; 1996 Nov; 89(11):1053-6. PubMed ID: 8903286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
    Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
    Highton A; Quell J
    J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
    Feldman SR; Mills M; Brundage T; Eastman WJ
    J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
    Bowman PH; Maloney JE; Koo JY
    J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
    Tirado-Sánchez A; Ponce-Olivera RM
    Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
    Guzzo C; Lazarus G; Goffe BS; Katz HI; Lowe NJ; Pincus SH
    J Am Acad Dermatol; 1996 Mar; 34(3):429-33. PubMed ID: 8609254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
    White S; Vender R; Thaçi D; Haverkamp C; Naeyaert JM; Foster R; Martinez Escribano JA; Cambazard F; Bibby A
    Am J Clin Dermatol; 2006; 7(3):177-84. PubMed ID: 16734505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
    Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
    J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
    Coynik D
    Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions.
    Kang S; Yi S; Griffiths CE; Fancher L; Hamilton TA; Choi JH
    Br J Dermatol; 1998 Jan; 138(1):77-83. PubMed ID: 9536226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
    Silver S; Tuppal R; Gupta AK; Clonier F; Olesen M; Leeder R; Taraska V
    J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
    Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
    J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
    Kin KC; Hill D; Feldman SR
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
    McCormack PL
    Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and topical therapy.
    Lebwohl M
    Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.